JP2023549555A - 抗ｍａｒｃｏ抗体及びその使用 - Google Patents

抗ｍａｒｃｏ抗体及びその使用 Download PDF

Info

Publication number
JP2023549555A
JP2023549555A JP2023529918A JP2023529918A JP2023549555A JP 2023549555 A JP2023549555 A JP 2023549555A JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023549555 A JP2023549555 A JP 2023549555A
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
cdr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023529918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549555A5 (https=
Inventor
ナディン ジャーチャン
ミシェル ストレウリ
シー ヤン
リンダ リャン
ベンカタラマン スリラム
ジョシュア ポラック
ブラディスラバ ユリッチ
リネア ヘッグブロム
カラ モヒカ
レナード ジー． プレスタ
サヤンタン ミトラ
Original Assignee
パイオニア イミュノセラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パイオニア イミュノセラピューティクス インコーポレイテッド filed Critical パイオニア イミュノセラピューティクス インコーポレイテッド
Publication of JP2023549555A publication Critical patent/JP2023549555A/ja
Publication of JP2023549555A5 publication Critical patent/JP2023549555A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023529918A 2020-11-18 2021-11-18 抗ｍａｒｃｏ抗体及びその使用 Pending JP2023549555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063115272P 2020-11-18 2020-11-18
US63/115,272 2020-11-18
US202163244662P 2021-09-15 2021-09-15
US63/244,662 2021-09-15
PCT/US2021/059955 WO2022109178A1 (en) 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023549555A true JP2023549555A (ja) 2023-11-27
JP2023549555A5 JP2023549555A5 (https=) 2024-11-20

Family

ID=81588283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023529918A Pending JP2023549555A (ja) 2020-11-18 2021-11-18 抗ｍａｒｃｏ抗体及びその使用

Country Status (10)

Country Link
US (2) US11572407B2 (https=)
EP (1) EP4247419A4 (https=)
JP (1) JP2023549555A (https=)
KR (1) KR20230121759A (https=)
AU (1) AU2021382658A1 (https=)
CA (1) CA3198579A1 (https=)
IL (1) IL302874A (https=)
MX (1) MX2023005841A (https=)
TW (1) TW202237648A (https=)
WO (1) WO2022109178A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11572407B2 (en) 2020-11-18 2023-02-07 Pionyr Immunotherapeutics, Inc. Anti-MARCO antibodies and uses thereof
CA3238769A1 (en) * 2021-11-23 2023-06-01 William Brondyk Anti-ngf antibodies and uses thereof
WO2024059256A1 (en) * 2022-09-15 2024-03-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer
WO2024081807A2 (en) * 2022-10-12 2024-04-18 Massachusetts Institute Of Technology Library-scale methods for polypeptide functional analysis
WO2025102054A1 (en) * 2023-11-09 2025-05-15 Massachusetts Institute Of Technology Methods of screening for secreted functional molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535508A (ja) * 2010-08-13 2013-09-12 ベイラー リサーチ インスティテュート 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
US20180171021A1 (en) * 2015-06-01 2018-06-21 The Rockefeller University Anti-Tumor Agents and Methods of Use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916766A (en) 1996-05-23 1999-06-29 Smithkline Beecham Corporation Human marco scavenger receptor
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
JP2010534335A (ja) * 2007-07-24 2010-11-04 アイエスエス イミューン システム スティミュレーション アーベー 全身性エリテマトーデス感受性を予測するための方法及び手段
WO2009114547A2 (en) 2008-03-10 2009-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced dendritic cells for cancer immunotherapy
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2017062363A1 (en) 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CN110709422B (zh) 2017-04-19 2023-12-26 马伦戈治疗公司 多特异性分子及其用途
TWI828625B (zh) 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
EP3668899A4 (en) 2017-08-18 2020-09-02 Celdara Medical, LLC CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES
WO2019068007A1 (en) 2017-09-28 2019-04-04 Immpact-Bio Ltd. UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)
US20210000920A1 (en) 2017-12-22 2021-01-07 Atossa Therapeutics, Inc. Intraductal methods of treatment of breast disorders
AU2019228381B2 (en) 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
BR112021006100A2 (pt) 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
AU2019394364A1 (en) * 2018-12-05 2021-06-17 The Council Of The Queensland Institute Of Medical Research Rank antagonists and uses therefor
EP3906055A4 (en) 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
JP2022519378A (ja) 2019-02-08 2022-03-23 グッド ティー セルズ、 インコーポレイテッド がん治療のためのｔ細胞の活性化方法
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
JP2022536598A (ja) 2019-05-07 2022-08-18 イミューニコム， インコーポレイテッド 体外アフェレーシスによるチェックポイント阻害剤に対する応答の上昇
JP2022536684A (ja) 2019-06-11 2022-08-18 マイエロイド・セラピューティクス，インコーポレーテッド マクロファージ特異的エンゲージャー組成物およびその使用方法
EP4003994A4 (en) 2019-07-31 2023-09-13 Oncour Pharma, Inc. TREATMENT OF EVASIVE IMMUNE TUMORS
US11572407B2 (en) 2020-11-18 2023-02-07 Pionyr Immunotherapeutics, Inc. Anti-MARCO antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535508A (ja) * 2010-08-13 2013-09-12 ベイラー リサーチ インスティテュート 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
US20180171021A1 (en) * 2015-06-01 2018-06-21 The Rockefeller University Anti-Tumor Agents and Methods of Use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNA-MARIA GEORGOUDAKI ET AL.: ""Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and M", CELL REPORTS, vol. 15, no. 9, JPN6025043971, 2016, pages 2000 - 2011, ISSN: 0005716222 *
OUTI ELOMAA ET AL.: ""Structure of the Human Macrophage MARCO Receptor and Characterization of Its Bacteria-binding Regi", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 8, JPN6025043970, 1998, pages 4530 - 4538, ISSN: 0005716221 *

Also Published As

Publication number Publication date
US11572407B2 (en) 2023-02-07
IL302874A (en) 2023-07-01
US20220153832A1 (en) 2022-05-19
MX2023005841A (es) 2023-08-16
CA3198579A1 (en) 2022-05-27
EP4247419A4 (en) 2024-11-06
KR20230121759A (ko) 2023-08-21
TW202237648A (zh) 2022-10-01
US12378311B2 (en) 2025-08-05
WO2022109178A1 (en) 2022-05-27
AU2021382658A1 (en) 2023-07-06
US20240084000A1 (en) 2024-03-14
EP4247419A1 (en) 2023-09-27
WO2022109178A9 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
JP7069261B2 (ja) Ｃｄ７３特異的結合分子及びその使用
US12240910B2 (en) Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use
TWI731861B (zh) FcRH5之人源化及親和力成熟抗體及使用方法
US12378311B2 (en) Anti-MARCO antibodies and uses thereof
JP6931329B2 (ja) 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
JP7688579B2 (ja) 抗ｔｒｅｍ２抗体の使用方法
KR20230164243A (ko) Icos에 대한 항체
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
HK1258249A1 (zh) 用於测定icos表达的基因标志
JP7759996B2 (ja) 抗ｔｒｅｍ１抗体及び関連方法
EP4329806A1 (en) Anti-siglec compositions and uses thereof
CN116635073A (zh) 抗marco抗体和其用途
EA052033B1 (ru) Антитела к marco и их применение
HK40096227A (zh) 抗marco抗体和其用途
Nilvebrant et al. IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of the Antibody Society, December 5–8, 2011, San Diego, CA
HK40065337A (en) Anti-trem1 antibodies and related methods
EA049996B1 (ru) Антитело к siglec-10 (варианты)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260126